Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Victoria L. Webber"'
Autor:
Andrew H. Sims, J. Michael Dixon, Jeremy S. Thomas, Charlene Kay, Lorna Renshaw, Alexey A. Larionov, Victoria L. Webber, Arran K. Turnbull, Laura M. Arthur
Microsoft Excel workbook containing the following gene lists and information; A) 500 most variable genes from Figure 1D, B) differentially expressed genes between ILC and IDC at baseline and 3 months of treatment using Rank Products with a cut-off of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08dcbffa45856ce0757857d045152ce2
https://doi.org/10.1158/0008-5472.22404123.v1
https://doi.org/10.1158/0008-5472.22404123.v1
Autor:
J Michael Dixon, Charlene Kay, James Meehan, Arran K Turnbull, Carlos Martinez-Perez, Mark Gray, Victoria L. Webber
Publikováno v:
Kay, C, Martinez-Perez, C, Meehan, J, Gray, M, Webber, V, Dixon, J M & Turnbull, A K 2021, ' Current trends in the treatment of HR+/HER2+ breast cancer ', Future oncology, vol. 17, no. 13, pp. 1665-1681 . https://doi.org/10.2217/fon-2020-0504
Treatment for HR+/HER2+ patients has been debated, as some tumors within this luminal HER2+ subtype behave like luminal A cancers, whereas others behave like non-luminal HER2+ breast cancers. Recent research and clinical trials have revealed that a c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21e4987ef995055bd06183905ebc2590
https://www.pure.ed.ac.uk/ws/files/252557484/Current_trends_in_the_treatment_of_hormone_receptor_positive_HER2_positive_breast_cancer.pdf
https://www.pure.ed.ac.uk/ws/files/252557484/Current_trends_in_the_treatment_of_hormone_receptor_positive_HER2_positive_breast_cancer.pdf
Autor:
Arran K Turnbull, Jeremy Thomas, Lorna Renshaw, Andrew H. Sims, Laura M. Arthur, Victoria L. Webber, Charlene Kay, J Michael Dixon, Alexey Larionov
Publikováno v:
Cancer research. 74(19)
Invasive lobular carcinoma (ILC) accounts for approximately 10% to 15% of breast carcinomas, and although it responds poorly to neoadjuvant chemotherapy, it appears to respond well to endocrine therapy. Pre- and on-treatment (after 2 weeks and 3 mont